Continued from page 2

“Each cell type has different uses for different purposes,” said Mr. Siegel, referring to embryonic, adult and induced pluripotent stem cells, in which adult stem cells are reprogrammed to act like desired cells.

Some cells are better to understand the root causes of disease, some might be ready for cell transplant and others may be used as tools for drug discovery, Mr. Siegel said.

“We need them all,” he said.

In Maryland, a spokeswoman for the Maryland Stem Cell Research Commission declined to comment on the Lozier report. The commission held its sixth annual research symposium Tuesday at the Johns Hopkins University School of Medicine. Several of its presentations were on induced pluripotent stem cell technologies.

Separately, the National Institutes of Health remains a major player in all kinds of stem cell research: In fiscal 2012, it issued $146.5 million for embryonic stem cell research and $504 million for non-embryonic projects; both were record-breaking amounts for the agency.